PDSB - PDS Biotech gains 10% after PDS0101 combo shows tumor regression in HPV+ cancer patients

PDS Biotechnology (PDSB) presents interim data from Phase 2 trial studying PDS0101 (Versamune-HPV16) in combination with two investigational immune-modulating agents: bintrafusp alfa (M7824) and NHS-IL12 (M9241) in both checkpoint inhibitor naïve and refractory patients with advanced HPV-associated cancers that have progressed or returned after treatment. Data from a total of 25 patients were available as of the time of presentation, of which data from original 14 HPV16+ patients were published on May 19.Data from additional 7 HPV16-negative patients and 4 HPV16+ patients who are checkpoint inhibitor refractory became available after the abstract submission.The following update was provided on the initial 6 HPV16+ patients who had NOT been treated with checkpoint inhibitors (checkpoint inhibitor naïve):83% (5/6) of the patients demonstrated an objective response rate ((ORR)) (tumor reduction >30%).100% are still alive at 8 months.80% (4/5) of patients who had an objective response still have an ongoing response at 8 months; 1 patient

For further details see:

PDS Biotech gains 10% after PDS0101 combo shows tumor regression in HPV+ cancer patients